Trials / Terminated
TerminatedNCT00439192
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
A Multicenter, Randomized, Double-Blind, Parallel Group, Phase II, Forced Dose Titration Study to Investigate the Efficacy and Safety of 400mg and 600mg ELB245 Given Once Daily for 12 Weeks (8 + 4 Weeks) Versus Placebo and Versus 4mg Tolterodine Given Once Daily in Patients With Incontinent Overactive Bladder (OAB)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 275 (estimated)
- Sponsor
- elbion AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo , when administered to patients with OAB and to compare the efficacy of escalating doses of ELB245 versus the standard treatment tolterodine, when administered to patients with OAB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ELB245 | |
| DRUG | Tolterodine |
Timeline
- Start date
- 2007-02-01
- Completion
- 2007-08-01
- First posted
- 2007-02-23
- Last updated
- 2007-08-08
Locations
31 sites across 3 countries: Germany, Poland, Sweden
Source: ClinicalTrials.gov record NCT00439192. Inclusion in this directory is not an endorsement.